Cadila gets USFDA nod for Zonisamide

Cadila Healthcare has received approval from USFDA to market Zonisamide capsules of 25 mg, 50 mg and 100 mg. The drug falls in the anti-epileptic segment.

According to a release issue by Cadila to the BSE today, the company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA).